Clinical Trials Browser

Phase 1/2 × INDUSTRY × Neoplastic Processes × Clear all

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplastic Processes, Pancreatic Neoplasms, Thoracic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT04601584 2024-03-06

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

Phase 1/2 Recruiting

36 enrolled

LymphoidOther hematologic neoplasm

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01386580 2015-01-22

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Phase 1/2 Completed

84 enrolled

BreastCNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases, Glioma, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Nervous System Diseases, Nervous System Neoplasms, Pathologic Processes, Central Nervous System Neoplasms

Clinical Trials

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.